AR067084A1 - Dispersion solida que contiene revaprazan y procedimiento para la preparacion de la misma. composicion farmaceutica. - Google Patents

Dispersion solida que contiene revaprazan y procedimiento para la preparacion de la misma. composicion farmaceutica.

Info

Publication number
AR067084A1
AR067084A1 ARP080102637A ARP080102637A AR067084A1 AR 067084 A1 AR067084 A1 AR 067084A1 AR P080102637 A ARP080102637 A AR P080102637A AR P080102637 A ARP080102637 A AR P080102637A AR 067084 A1 AR067084 A1 AR 067084A1
Authority
AR
Argentina
Prior art keywords
solid dispersion
pharmaceutical composition
revapraze
procedure
preparation
Prior art date
Application number
ARP080102637A
Other languages
English (en)
Inventor
Young-Joon Park
Chang-Keun Hyun
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of AR067084A1 publication Critical patent/AR067084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una dispersion solida en la cual las partículas de revaprazán son modificadas en la superficie con un polímero soluble en agua, un sacárido soluble en agua, un tensioactivo, o una mezcla de los mismos, y un procedimiento para preparar la misma. La presente provee también una composicion farmacéutica que contiene la dispersion solida y un procedimiento para preparar la composicion farmacéutica. Reivindicacion 5: La dispersion solida de acuerdo con la reivindicacion 1, caracterizada porque las partículas de revaprazán son modificadas en la superficie con polivinilpirrolidona, éster de ácido graso de sacarosa y aceite de ricino hidrogenado o natural glicolado polioxietileno.
ARP080102637A 2006-12-22 2008-06-20 Dispersion solida que contiene revaprazan y procedimiento para la preparacion de la misma. composicion farmaceutica. AR067084A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060132722 2006-12-22
KR1020070135270A KR100954828B1 (ko) 2006-12-22 2007-12-21 레바프라잔 함유 고체분산체 및 그의 제조방법

Publications (1)

Publication Number Publication Date
AR067084A1 true AR067084A1 (es) 2009-09-30

Family

ID=39562674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102637A AR067084A1 (es) 2006-12-22 2008-06-20 Dispersion solida que contiene revaprazan y procedimiento para la preparacion de la misma. composicion farmaceutica.

Country Status (20)

Country Link
US (1) US8663658B2 (es)
EP (1) EP2101737B1 (es)
JP (1) JP5484910B2 (es)
KR (1) KR100954828B1 (es)
CN (1) CN101600419B (es)
AR (1) AR067084A1 (es)
AU (1) AU2007339080B2 (es)
BR (1) BRPI0720472A2 (es)
CA (1) CA2673536A1 (es)
ES (1) ES2496166T3 (es)
HK (1) HK1138517A1 (es)
MX (1) MX2009006105A (es)
MY (1) MY146557A (es)
PA (1) PA8784701A1 (es)
PE (1) PE20090424A1 (es)
RU (1) RU2461382C2 (es)
SA (1) SA08290368B1 (es)
TW (1) TW200927124A (es)
WO (1) WO2008078922A1 (es)
ZA (1) ZA200905094B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673536A1 (en) 2006-12-22 2008-07-03 Yuhan Corporation Revaprazan-containing solid dispersion and process for the preparation thereof
CN101874775B (zh) * 2010-05-31 2013-03-13 沈阳药科大学 盐酸瑞伐拉赞纳米混悬剂及其制备方法
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
KR101739815B1 (ko) * 2010-12-01 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물
KR101730865B1 (ko) * 2011-02-11 2017-04-27 주식회사유한양행 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
KR101739818B1 (ko) * 2011-05-20 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물
KR101739820B1 (ko) * 2012-03-28 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
WO2015175505A1 (en) * 2014-05-15 2015-11-19 Lundbeck Llc Tetrabenazine modified release formulation
CN106456556A (zh) * 2014-06-18 2017-02-22 豪夫迈·罗氏有限公司 包含非离子性表面活性剂的新型药物组合物
CN104825410A (zh) * 2015-05-04 2015-08-12 海南海力制药有限公司 一种盐酸瑞伐拉赞片及其制备方法
CN105288636B (zh) * 2015-12-11 2019-05-07 北京科莱博医药开发有限责任公司 增溶体系、固体分散体及药物制剂
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions
CN105687150B (zh) * 2016-03-15 2019-12-10 常州市第四制药厂有限公司 一种盐酸瑞伐拉赞组合物及制备方法
CN106361721A (zh) * 2016-08-31 2017-02-01 佛山市弘泰药物研发有限公司 一种盐酸瑞伐拉赞胶囊及其制备方法
PT110585B (pt) * 2018-02-22 2021-04-22 Hovione Farmaciencia Sa Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização
JPWO2020261619A1 (es) 2019-06-26 2020-12-30
EP3989940A1 (en) 2019-06-26 2022-05-04 Ricoh Company, Ltd. Instantly soluble particle and method for producing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255125A (ja) 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
KR0157075B1 (ko) * 1994-08-13 1998-11-16 김태훈 신규의 피리미딘 유도체 및 그의 제조방법
ES2201112T3 (es) * 1994-08-13 2004-03-16 Yuhan Corporation Nuevos derivados de pirimidina y procedimientos para su preparacion.
EP0834314B1 (en) * 1995-06-12 2003-01-15 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
EP1227797B1 (en) * 1999-11-12 2005-01-12 Abbott Laboratories Solid dispersion pharmaceutical formulations
AU782469B2 (en) * 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs
HUP0303700A3 (en) * 2000-07-17 2006-07-28 Astellas Pharma Inc Chuo Ku Pharmaceutical composition improved in peroral absorbability
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1275377B1 (en) * 2001-07-11 2003-06-18 Apr Applied Pharma Research S.A. Granulates containing liposoluble substances and process of preparation thereof
KR20040081123A (ko) * 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
ES2280835T3 (es) * 2002-12-19 2007-09-16 Pharmacia Corporation Formulacion no higroscopica que comprende un farmaco higroscopico.
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
CN100563658C (zh) * 2003-11-14 2009-12-02 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
US20060165797A1 (en) 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
CA2673536A1 (en) 2006-12-22 2008-07-03 Yuhan Corporation Revaprazan-containing solid dispersion and process for the preparation thereof

Also Published As

Publication number Publication date
AU2007339080B2 (en) 2012-09-27
US8663658B2 (en) 2014-03-04
BRPI0720472A2 (pt) 2014-01-14
KR20080059083A (ko) 2008-06-26
CA2673536A1 (en) 2008-07-03
JP2010513474A (ja) 2010-04-30
WO2008078922A1 (en) 2008-07-03
EP2101737A4 (en) 2013-05-01
HK1138517A1 (en) 2010-08-27
CN101600419A (zh) 2009-12-09
US20100041688A1 (en) 2010-02-18
JP5484910B2 (ja) 2014-05-07
RU2009128206A (ru) 2011-01-27
KR100954828B1 (ko) 2010-04-27
PA8784701A1 (es) 2009-07-23
EP2101737A1 (en) 2009-09-23
CN101600419B (zh) 2012-05-09
PE20090424A1 (es) 2009-05-15
RU2461382C2 (ru) 2012-09-20
ES2496166T3 (es) 2014-09-18
ZA200905094B (en) 2010-09-29
SA08290368B1 (ar) 2011-10-08
MY146557A (en) 2012-08-30
TW200927124A (en) 2009-07-01
MX2009006105A (es) 2009-06-18
EP2101737B1 (en) 2014-06-18
AU2007339080A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
AR067084A1 (es) Dispersion solida que contiene revaprazan y procedimiento para la preparacion de la misma. composicion farmaceutica.
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
CR7999A (es) Metodos y composiciones farmaceuticas para la obtencion confiable de niveles aceptables de testosterona en suero
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
PE20030318A1 (es) Goma de mascar y composiciones de confiteria quitamanchas dentales y procedimientos de preparacion y uso de las mismas
AR077411A2 (es) Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion.
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
MX2009004439A (es) Composicion de ibuprofeno.
NZ610465A (en) Clevidipine emulsion formulations containing antimicrobial agents
WO2006122223A3 (en) Strategies for delivery of active agents using micelles and particles
AR039379A1 (es) Matriz para la liberacion sostenida, invariable e independiente de compuestos activos
AR050717A1 (es) Composiciones farmaceuticas
NO20090654L (no) Anvendelse av f DPA(n-6) oljer i formuleringer for barn
WO2008002121A3 (en) A self-emulsifying composition for poorly bioavailable drugs
TW200833736A (en) Polytrimethylene ether glycol esters
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
AR056268A1 (es) Tabletas que comprenden una sustancia biologicamente activa y un excipiente
AR060580A1 (es) Elastomeros de silicona que contienen antisepticos
AR073816A1 (es) Sistema de nanoparticulas, proceso para la preparacion de las mismas, uso de las mismas, composicion fotoprotectora, proceso para la preparacion de la misma, y metodo de prevencion de enfermedades de la piel
CL2015003596A1 (es) Formulación de liberación modificada
AR094941A1 (es) Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
AR055659A1 (es) Composicion fungicida
CL2008003006A1 (es) Uso de ester metilico del acido (-)-(3ar,4s,7ar)-4-hidroxi-4-m-toliletinil-octahidro-indol-1-carboxilico en base libre o en forma de sal para el tratamiento, prevencion o retraso de la progresion de la disquinesia de parkinson asociada a l-dopa; uso de la composicion farmaceutica; uso de una composicion que ademas comprende l-dopa.
CO6630089A2 (es) Composicion de encapsulamiento de liberacion rapida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal